{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T22:20:58Z","timestamp":1767824458370,"version":"3.49.0"},"reference-count":10,"publisher":"Royal College of Psychiatrists","issue":"3","license":[{"start":{"date-parts":[[2018,1,2]],"date-time":"2018-01-02T00:00:00Z","timestamp":1514851200000},"content-version":"unspecified","delay-in-days":9804,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Psychiatry"],"published-print":{"date-parts":[[1991,3]]},"abstract":"<jats:p>To our knowledge Pisa syndrome in childhood or adolescence has not previously been described. The syndrome developed in an adolescent girl following administration of neuroleptic medication for psychotic features, and was transiently thought to be abnormal illness behaviour. This case emphasises the need for early diagnosis and rapid effective treatment.<\/jats:p>","DOI":"10.1192\/bjp.158.3.422","type":"journal-article","created":{"date-parts":[[2008,10,15]],"date-time":"2008-10-15T17:24:42Z","timestamp":1224091482000},"page":"422-423","source":"Crossref","is-referenced-by-count":10,"title":["Pisa Syndrome in an Adolescent on Neuroleptic Medication"],"prefix":"10.1192","volume":"158","author":[{"given":"Jeremy","family":"Turk","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bryan","family":"Lask","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"170","published-online":{"date-parts":[[2018,1,2]]},"reference":[{"key":"S0007125000108025_ref7","first-page":"140","article-title":"Neurolepticrelated dyskinesias in autistic children: a prospective study","volume":"21","author":"Perry","year":"1985","journal-title":"Psychopharmacology Bulletin"},{"key":"S0007125000108025_ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-7138(09)61066-9"},{"key":"S0007125000108025_ref3","doi-asserted-by":"publisher","DOI":"10.1007\/BF00316159"},{"key":"S0007125000108025_ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(85)80207-9"},{"key":"S0007125000108025_ref1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.153.1.107"},{"key":"S0007125000108025_ref9","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.149.4.524b"},{"key":"S0007125000108025_ref8","doi-asserted-by":"publisher","DOI":"10.1007\/BF01538282"},{"key":"S0007125000108025_ref10","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.146.1.93"},{"key":"S0007125000108025_ref2","volume-title":"Child and Adolescent Psychopharmacology","author":"Campbell","year":"1985"},{"key":"S0007125000108025_ref5","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1176\/ajp.141.1.20","article-title":"Tardive dyskinesia and other clinical consequences of neuroleptic treatment in children and adolescents","volume":"141","author":"Gualtieri","year":"1984","journal-title":"American Journal of Psychiatry"}],"container-title":["British Journal of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0007125000108025","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,17]],"date-time":"2019-05-17T22:36:23Z","timestamp":1558132583000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0007125000108025\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1991,3]]},"references-count":10,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1991,3]]}},"alternative-id":["S0007125000108025"],"URL":"https:\/\/doi.org\/10.1192\/bjp.158.3.422","relation":{},"ISSN":["0007-1250","1472-1465"],"issn-type":[{"value":"0007-1250","type":"print"},{"value":"1472-1465","type":"electronic"}],"subject":[],"published":{"date-parts":[[1991,3]]}}}